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Longitudinal multi-omics of host–
microbe dynamics in prediabetes
Wenyu Zhou1,12, M. reza Sailani1,12, Kévin contrepois1,12, Yanjiao Zhou2,3,12, Sara Ahadi1,12, Shana r. leopold2, Martin J. Zhang4, 
Varsha rao1, Monika Avina1, tejaswini Mishra1, Jethro Johnson2, Brittany lee-McMullen1, Songjie chen1, Ahmed A. Metwally1, 
thi Dong Binh tran2, Hoan Nguyen2, Xin Zhou2, Brandon Albright2, Bo-Young Hong2, lauren Petersen2, eddy Bautista2,  
Blake Hanson2, lei chen2, Daniel Spakowicz2, Amir Bahmani5, Denis Salins1, Benjamin leopold2, Melanie Ashland1,  
Orit Dagan-rosenfeld1, Shannon rego1, Patricia limcaoco1, elizabeth colbert6, candice Allister6, Dalia Perelman6, colleen craig6, 
eric Wei1,5, Hassan chaib1,5,7, Daniel Hornburg1, Jessilyn Dunn1, liang liang1, Sophia Miryam Schüssler-Fiorenza rose8,9,  
Kim Kukurba1, Brian Piening10, Hannes rost11, David tse4, tracey Mclaughlin6,7, erica Sodergren2, George M. Weinstock2* & 
Michael Snyder1,5,7*
Type 2 diabetes mellitus (T2D) is a growing health problem, but little is known about its early disease stages, its effects 
on biological processes or the transition to clinical T2D. To understand the earliest stages of T2D better, we obtained 
samples from 106 healthy individuals and individuals with prediabetes over approximately four years and performed 
deep profiling of transcriptomes, metabolomes, cytokines, and proteomes, as well as changes in the microbiome. This 
rich longitudinal data set revealed many insights: first, healthy profiles are distinct among individuals while displaying 
diverse patterns of intra- and/or inter-personal variability. Second, extensive host and microbial changes occur during 
respiratory viral infections and immunization, and immunization triggers potentially protective responses that are distinct 
from responses to respiratory viral infections. Moreover, during respiratory viral infections, insulin-resistant participants 
respond differently than insulin-sensitive participants. Third, global co-association analyses among the thousands of 
profiled molecules reveal specific host–microbe interactions that differ between insulin-resistant and insulin-sensitive 
individuals. Last, we identified early personal molecular signatures in one individual that preceded the onset of T2D, 
including the inflammation markers interleukin-1 receptor agonist (IL-1RA) and high-sensitivity C-reactive protein 
(CRP) paired with xenobiotic-induced immune signalling. Our study reveals insights into pathways and responses that 
differ between glucose-dysregulated and healthy individuals during health and disease and provides an open-access 
data resource to enable further research into healthy, prediabetic and T2D states.
T2D is a metabolic disorder that affects more than 400 million 
people worldwide1. Prediabetes, or intermediate hyperglycaemia, 
represents a high-risk state for developing T2D that is often undiag-
nosed. Approximately 5–10% of people with prediabetes will become 
diabetic each year, and up to 70% of individuals with prediabetes will 
eventually develop diabetes in their lifetime. Prediabetes and T2D are 
often associated with insulin resistance, where individuals produce 
insulin but are hyperglycaemic because their cells do not respond to 
insulin. Studying individuals with prediabetes and insulin resistance 
offers unique opportunities to investigate the earliest stages of diabetes, 
including its effect on biological processes and health.
The development of T2D involves complex and heterogeneous 
processes2,3, and individuals with diabetes show differences in both 
human host markers and gut microbiome signatures when compared 
with healthy individuals4,5. Furthermore, physiological stresses, such 
as viral infection, have been linked to the development of diabetes6–8. 
However, a global and simultaneous profile of both host and microbial 
molecules in prediabetes is lacking. We still do not have a systematic 
understanding of how healthy individuals and those with prediabetes 
differ at baseline or change over time or in response to stresses such 
as viral infections, and whether such responses depend on insulin- 
resistance status.
To obtain a better understanding of the biological processes associ-
ated with both healthy individuals and those with T2D at its earliest 
stages, we performed a detailed longitudinal analysis of individuals 
with various early impairments in glucose control (for example, insulin 
resistance). We carried out deep profiling of the human gut and nasal 
microbiomes, as well as host circulating blood during periods of health 
and stress. Our study reveals that many host biochemical and micro-
bial components are stable over time when healthy, but can undergo 
dynamic and marked changes in response to viral infection and other 
perturbations. Notably, these changes differ between insulin-sensitive 
and insulin-resistant individuals. As well as revealing biological 
insights, our study provides a rich, open-access resource of longitudi-
nal data that allows deep mining of host and microbial changes at an 
individual level.
Overview: cohort, sample collection and assays
We followed 106 participants for up to almost four years (Fig. 1a; 
Stanford IRB No. 23602), except for one individual who was followed 
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for seven years; early findings for this individual have been published 
previously8. The cohort comprised 55 women and 51 men, with ages 
ranging from 25 to 75 years old and body mass indexes (BMI) ranging 
from 19 to 41 kg m–2 (Supplementary Table 1).
Samples were generally taken every three months when participants 
were self-reported as healthy. In total, 624 healthy baselines were pro-
filed, with each participant having 1–56 healthy visits during the study 
(Fig. 1b, Extended Data Fig. 1a, b). Additional visits during periods of 
environmental or medical stress included events of respiratory viral 
infection (RVI; 54 episodes in 32 participants with a total of 203 vis-
its) and immunization (29 episodes in 22 participants with a total of 
123 visits) with dense sampling in the early phase (two time points 
during days 1–6), a later phase (day 7–14) and the recovery phase 
(at weeks 3 and 5; Fig. 1a, Extended Data Fig. 1c). Samples were also 
taken when other stresses occurred, such as weight gain, antibiotic 
treatment, colonoscopy, travel and other self-reported acute severe 
stresses, but these were less frequent (Fig. 1b). In total, we profiled 
1,092 time points across all participants, with a median of seven visits 
(including a median of five healthy baseline visits) spanning a median 
of 1.6 years per participant (Supplementary Table 1).
At each visit, blood was collected for host molecular ’omics profil-
ing and two types of sample (stool and nasal swab) were collected for 
microbial profiling9. A battery of molecular and clinical laboratory tests 
were performed and complemented with self-reported online surveys, 
which documented changes in medication, physical activity, diet pref-
erence and perceived stress level (Fig. 1c). Blood was fractionated into 
peripheral blood monocytes (PBMCs), plasma and serum. Each partic-
ipant’s exome was sequenced once; otherwise, for each visit, we profiled 
13,379 transcripts (using Ribo-minus RNA sequencing (RNA-seq)) 
from PBMCs, 722 metabolites (using untargeted liquid chromatog-
raphy with tandem mass spectrometry (LC–MS/MS)), 302 proteins 
(using sequential window acquisition of all theoretical mass spectra 
(SWATH-MS)) from plasma, and 62 cytokines and growth factors 
from serum. In addition, thousands of gut and nasal microbial taxa 
and predicted genes were profiled using 16S sequencing (for quality 
controls, see Methods and Extended Data Fig. 1d, e; Supplementary 
Table 4 lists all molecules profiled). Note that all visits were intensively 
characterized by 51 clinical laboratory tests. Supplementary Table 3 lists 
all study collections, types of ‘omics’ measurement assayed (referred 
to here as omes) and metadata; 823 visits were profiled with at least 
six multi-omic assays. Overall, we generated a rich data set containing 
millions of molecular and microbial measurements (Fig. 1d). Notably, 
most (n = 83) of the individuals consented to make their data open 
access, thus providing a valuable resource (available at https://portal.
hmpdacc.org/ and http://med.stanford.edu/ipop.html).
Because of the interest in studying prediabetes, insulin resist-
ance and T2D, at each visit we measured haemoglobin A1C (A1C; 
a measure of average glucose over three months: diabetic ≥ 6.5% > 
prediabetic ≥ 5.7%) and fasting glucose (diabetic ≥ 126 mg dl–1 > 
prediabetic ≥ 100 mg dl–1)10; 84 participants underwent an annual oral 
glucose tolerance test (OGTT: diabetic glucose ≥ 200 mg dl–1 > pre-
diabetic ≥ 140 mg dl–1 at 2 h, Supplementary Table 2). Upon entering 
the study, 51 participants had prediabetes and 9 had diabetes accord-
ing to any of the three criteria above. Sixty-six participants without 
medical contraindications underwent the insulin suppression test11 to 
assess their insulin resistance or sensitivity through steady-state plasma 
glucose (SSPG); 31 participants were classified as insulin-sensitive 
(SSPG < 150 mg dl–1) and 35 as insulin-resistant (SSPG ≥ 150 mg dl–1) 
with similar profiles in age, sex and ethnicity (Supplementary Table 1). 
Although this study focuses on different phenotypes and changes that 
depend on insulin resistance as defined by SSPG, the comparison of 
different glucose dysregulation defined by A1C, fasting glucose, OGTT 
and SSPG and their progression during the study are reported in a 
companion paper12.
Variation in healthy baseline profiles
The extensive longitudinal profiling enabled us to assess variation 
within an individual over time, between individuals, and in different 
types of molecule and microorganism. We first quantified the disper-
sion level of multi-omic measurements from all healthy visits across the 
cohort by examining their interquartile ranges (IQRs). We observed 
complex and variable patterns of our measurements depending on the 
’omic type, analyte expression, and participant structure in our cohort 
(Extended Data Fig. 2a, b, Supplementary Table 4). We evaluated the 
proportion of total variance explained by participant structure in the 
cohort using intra-class correlation (ICC) from linear mixed effect 
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Fig. 1 | Summary of study design, cohort details and data. a, Samples 
were collected from 106 participants for nearly four years, with quarterly 
healthy visits and dense sampling during stress events. b, Summary of 
visits in each category and categorization of participants as insulin-
sensitive or insulin-resistant. c, Sample sources, types of multi-omic assay 
and number for each data type profiled per visit. d, Conceptual illustration 
of the data structure for downstream analysis. Supplementary Table 3 lists 
the number of visits and assays profiled for each participant.
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(LME) models in each multi-omic analyte (Fig. 2a, Supplementary 
Table 5). Clinical laboratory tests (labs) and cytokine profiles were 
the most personally distinct (for example, more variable between indi-
viduals), whereas transcripts had similar variance within individuals 
as between individuals. Gut microbial taxa, mostly low-abundance 
ones, showed significantly higher inter-personal variability than their 
predicted genes (P = 7.26 × 10–15; Extended Data Fig. 2c). We quanti-
fied the separation pattern between participants by individuality scores 
(ind_score). The bottom panel of Fig. 2a shows the separation pattern 
between participants based on the top 30 most personally distinct ana-
lytes. As more variables were selected, clusters of individuals overlapped 
more with a decreased individuality score (Supplementary Table 6). 
Similarly, the degree of separation and individuality score differ among 
omes depending on the inter-personal variability in analytes from 
each ome (Extended Data Fig. 2d). We found the highest individual 
separation (ind_score = 0.165) for clinical labs and the lowest separa-
tion (ind_score = 0.007) for transcripts.
We also assessed the influence of time on healthy baseline 
variation within individuals, with a specific emphasis on markers 
that increased or decreased monotonically over time. We identi-
fied both host molecules and gut microorganisms that significantly 
correlated, positively or negatively, with time (examples in Extended 
Data Fig. 3a, b, Supplementary Table 7). Among markers that decreased 
over time, some have been described previously (for example, alka-
line phosphatase, ALKP13; q = 1.77 × 10–33), and some have not, 
to our knowledge (for example, corpuscular haemoglobin, MCH; 
q = 6.08 × 10–14). Several microbiome genera also decreased over 
time, including Erysipelotrichaceae unclassified, Butyricicoccus, and 
Akkermansia (q < 0.05). Expanded ageing-related results will be 
presented elsewhere (submitted).
Factors that correlate with insulin resistance
As many of our participants were characterized with respect to insu-
lin resistance, we sought to characterize co-associations using two 
approaches: regression analysis with SSPG values and co-association 
with insulin-sensitive and insulin-resistant participants (association 
of analytes with A1C, high-sensitivity C-reactive protein (HSCRP) 
and other clinical measurements are described below and in more 
detail in the companion paper12). At constant BMI, SSPG values 
rarely varied14 per participant in our study, and after correcting for 
BMI, age and sex, we found 85 ’omic measurements and clinical labs 
that correlated significantly with SSPG levels (Fig. 2b, Supplementary 
Table 8, q < 0.1); 75 were repeatedly observed using correlational anal-
ysis with insulin-resistant/insulin-sensitive classification (Extended 
Data Fig. 3c, Supplementary Table 9). As reported previously, triglyc-
erides were positively associated with SSPG, whereas high-density 
lipoprotein (HDL) was inversely correlated with SSPG15,16. We also 
found that SSPG positively associated with increased inflammation 
and immune responses, as evident by neutrophil absolute count 
(q = 0.028) and white blood cell count (q = 0.066) from clinical labo-
ratory tests. Although these complete blood count values were still in 
the normal range, these observations highlight the association between 
inflammation and insulin resistance17,18. Insulin resistance is also 
associated with altered lipid biology, and levels of several long-chain 
and polyunsaturated fatty acids correlated positively with SSPG. 
Notable metabolites whose levels correlated inversely with insulin-re-
sistant/insulin-sensitive classification included indolelactic acid19 
(q = 0.13) and hippuric acid (q = 0.043), which inversely correlate 
with metabolic syndrome and are strong markers of gut microbiome 
diversity20. Consistent with our metabolomics, the genus Blautia, 
which inversely correlates with hippuric acid, was positively corre-
lated with SSPG (q = 0.045), in agreement with reports of a positive 
correlation between this genus and impaired glucose tolerance and 
diabetes21. On the other hand, the genera Odoribacter (q = 0.028), 
Oscillibacter (q = 0.011), and Pseudoflavonifracter (q = 0.0007) were 
negatively associated with SSPG, consistent with previous findings 
that Odoribacter is more abundant in healthy control individuals than 
in patients with non-alcoholic fatty liver disease22, in whom insulin 
resistance is common. Altogether, insulin resistance was associated with 
higher inflammation and altered lipid metabolism, which might cause 
insulin-resistant participants to have impaired responses to additional 
stresses, as reported previously19 and below.
Pathways associated with respiratory viral infections
To better understand the changes that occur during RVI, we grouped 
the time points into five categories: healthy time points before 
RVI (–H, less than 186 days before the first RVI visit), early events 
(EE, days 1–6 after infection), late events (EL, days 7–14 after infec-
tion), recovery (RE, days 15–40 after infection) and healthy time points 
after RVI (+H, less than 186 days after the last RVI visit; Extended 
Data Fig. 1c). To identify molecules that deviated significantly from 
healthy baselines (–H and +H) during RVI, we used area under 
the curve (AUC) statistics to test for differential expression over 
time and paired t-tests for category-specific changes (for example, 
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Fig. 2 | Variances observed among health visits. We characterized 624 
healthy baselines. a, Top, intra-class correlation (ICC) levels in analytes 
from each ’ome (gut microbes, median 32.65; gut microbial genes, 
median 19.19, P = 7.261 × 10−15 by Wilcoxon-rank test, two-sided). 
Bottom, separation pattern by multidimensional scaling (MDS) among 
participants defined by the top 30 most personally distinct analytes. 
Fourteen participants are shown in different colours, with healthy visits 
presented as dots bound by contours denoting personal variable space. 
b, Expression of analytes significantly associated with SSPG in healthy 
baselines. Red, increased expression; blue, decreased expression. Pink, 
clinical laboratory tests; red, cytokines; grey, metabolites; orange, proteins; 
dark green, gut microbes at the genus level per row of the heatmap. 
HDL, high-density lipoprotein; TGL, triglycerides; NEUTAB, neutrophil 
absolute count; uncl., unclassified; WBC, white blood cell count; EGFR, 
estimated glomerular filtration rate; GROA, also as CXCL1, growth-
regulated alpha protein. Undefined abbreviations are protein symbols.
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EE versus baseline; see Methods, Extended Data Fig. 4a, b). We identi-
fied 2,026 transcripts, 11 cytokines, 145 metabolites, 29 proteins, 11 gut 
microbial taxa, 30 nasal microbial taxa and 25 clinical laboratory tests 
that differed significantly from personal baselines based on the AUC 
test (q < 0.1; Supplementary Table 10). Integrated canonical pathway 
analyses, based on transcripts, proteins, cytokines and metabolites, 
identified pathways associated with defence responses, such as inter-
leukin signalling pathways, mTOR signalling23, and B cell and T cell 
receptor signalling24, among others25 (Fig. 3a, Supplementary Table 11, 
Extended Data Fig. 4c). We also identified the eukaryotic initiation fac-
tor 2 (eIF2) signalling pathway as induced early during RVI (EE stage); 
eIF2 gets activated by RVI and regulates pro-inflammatory cytokine 
expression26. Our analysis revealed molecular pathways that have, to 
our knowledge, not previously been shown to be dysregulated upon 
RVI (Fig. 3a). These include: 1) neurological pathways (for example, 
Huntington’s disease, q = 7.7 × 10–5; axonal guidance, q = 3.0 × 10–4; 
and neuroinflammatory signalling, q = 5.0 × 10–2; Fig. 3a, Extended 
Data Fig. 4d); 2) metabolic pathways (for example, insulin receptor 
signalling, q = 9.1 × 10–3; leptin signalling in obesity, q = 2.9 × 10–2); 
and 3) cardiac hypertrophy (q = 2.5 × 10–2; Extended Data Fig. 4e, 
Supplementary Table 11). Thus, a variety of biological pathways are 
altered during viral infection.
We further identified four major temporal clusters of molecules that 
were upregulated or downregulated during the course of RVI, as well as 
their top corresponding significant canonical pathways, microbial com-
munities, and clinical laboratory data (Fig. 3b, Supplementary Table 12, 
Extended Data Fig. 5a, b, and Discussion). As expected, the level of 
HSCRP and white blood cell count increased and HDL27 decreased 
upon RVI. We also observed many changes in the gut and nasal micro-
biome, including order Firmicutes and genus Odoribacter in the gut, 
which have been reported to decrease in patients with inflammation 
and RVI28,29. There was also an increase in Ruminococcus, Barnesiella, 
Alistipes, Rikenellaceae and Bacilli in the gut. Nasal microbiota also 
changed during RVI. We observed a general trend of milder or delayed 
nasal bacterial changes following the viral load during RVI (Fig. 3b), 
with the nasal microbial changes being the opposite of those seen in 
the gut in one participant, for example (Extended Data Fig. 5c), which 
suggested that viral and bacterial changes in the nares and gut might 
be coordinated. An in-depth analysis of this phenomenon will be 
presented elsewhere (submitted).
We next compared the responses to RVI between insulin-resist-
ant and insulin-sensitive participants. Insulin-resistant participants 
showed fewer changes after RVI than did insulin-sensitive participants 
(649 versus 873 significantly different molecules based on AUC test, 
q < 0.05, Supplementary Tables 13, 14; Supplementary Tables 17–19 
for stage-wise tests), and the affected pathways were different between 
the two groups (Fig. 3c, Supplementary Tables 15, 16). Notably, most 
immune-related pathways were upregulated at the EE stage in insu-
lin-sensitive participants, whereas almost no immune responses were 
evident until the EL stage in the insulin-resistant group. One key dif-
ference is that the acute phase response, which is a rapid inflamma-
tory response that protects against infection using non-specific defence 
mechanisms, was activated and sustained through the EL stage in 
insulin-sensitive individuals but not in insulin-resistant individuals 
(Extended Data Fig. 5d). Furthermore, in agreement with the impaired 
host response in the insulin-resistant group, we observed fewer changes 
in nasal microbiota taxa and predicted genes in the insulin-resistant 
group during RVI. Notably, the nasal genus Streptococcus became more 
abundant during the course of RVI only in insulin-sensitive partic-
ipants. Both the richness and the diversity of nasal microorganisms 
decreased significantly (q < 0.05) during RVI in insulin-sensitive but 
not insulin-resistant participants. It is possible that insulin-resistant 
participants have elevated baseline inflammation and an impaired 
immune response, which might hinder the coordination between the 
virus and bacteria during infection30. Moreover, changes in gut micro-
organisms differed between the insulin-resistant and insulin-sensitive 
groups (Supplementary Tables 13, 14). Overall, our results highlight 
the potential contribution of RVIs to the increased risk of developing 
metabolic disorders such as T2D in insulin-resistant individuals, and 
an impaired immune response to RVIs in these individuals.
Distinct responses to immunization
Among responses to influenza immunization, we identified 3,019 
transcripts, 9 metabolites, 6 proteins, 6 gut microbial taxa, 15 nasal 
microbial taxa and 23 clinical laboratory tests that differed signifi-
cantly from personal baselines (q < 0.1; Supplementary Tables 20, 21; 
Supplementary Tables 23–25 for stage-wise tests). Temporal patterns 
in differentially expressed molecules over time are shown in Extended 
Data Fig. 6a, b and Supplementary Table 22. Although there were 
similarities in pathway enrichment between immunization and RVI 
(Supplementary Tables 11, 21), there were many striking differences 
(Fig. 4a). For example, integrated canonical pathway analysis identi-
fied changes in immune pathways, such as B cell receptor signalling 
and NF-κB signalling, that differed between RVI and immunization 
responses (Supplementary Tables 21, 26, Extended Data Fig. 6d, e). 
Moreover, regulators in most of these pathways, such as IFNγ, IL-2, 
IL-3, IL-6 and BDNF, behaved differently (as indicated by Z-score) 
between RVI and immunization (q < 0.05; Extended Data Fig. 6c). 
Our analyses also showed that upon immunization, the type 1 diabetes 
(T1D), type 2 diabetes (T2D) and insulin receptor signalling (q < 0.05) 
pathways were predicted to be downregulated (Fig. 4a, Supplementary 
Table 21). These observations are in contrast to the host response to 
RVI, and suggest that immunization might protect against T1D and 
T2D risk31,32. In addition, we identified 11 and 6 gut microbial taxa 
that were dysregulated during RVI and immunization, respectively 
(Supplementary Tables 10, 20, Extended Data Fig. 7). Among immuni-
zation-induced changes, the family Erysipelotrichaceae, which is asso-
ciated with obesity33 and high fat intake34, was decreased, underscoring 
our observation that immunization inversely correlates with T1D and 
T2D signalling, which have overlapping biology with those metabolic 
disorders. These data reveal extensive differences in molecular path-
way changes upon RVI and immunization, and identify dysregulated 
pathways that include immune responses, metabolic and neurological 
pathways, as well as gut and nasal microorganisms.
Signatures for classification of stress events
We further investigated the power of multi-omic data to classify 
stress: healthy baselines versus RVI (Fig. 4b, Extended Data Fig. 8), 
and healthy baselines versus immunization (Extended Data Fig. 9). 
The multi-omes, metabolome, proteome and cytokines had the high-
est classification performance for discriminating RVI from healthy 
time points (88.6%, 80.1%, 77.1% and 76.9% classification accu-
racy, respectively, in logistic regression (LR) models). The top most 
predictive ’omics features selected by both LR and support vector 
machine (SVM) models included IP10 (a pro-inflammatory cytokine), 
followed by serum amyloid A1, immature dendritic cells (a PBMC cell 
type), C12H19NO2 (metabolite), serum amyloid A2, EFEMP1, LYM 
(lymphocyte percentage), GZMB (transcript), urocanic acid, betaine, 
and CD180 (transcript) (Supplementary Table 28). Using LR and 
SVM models to distinguish immunization from healthy time points 
(Extended Data Fig. 9, Supplementary Table 29), we revealed that mul-
ti-omes and metabolome markers had the highest accuracy (73.2% 
and 70.2%, respectively, in LR models). In addition, we defined the 
performances of pairwise combinations of multi-omes in classifying 
stress events from healthy baseline. The overall better performances of 
multi-omes, even with a smaller sample size, in classifying stress events 
from healthy baselines as compared to a single ’ome demonstrates the 
complementarity of different ’omes in describing the molecular pro-
cesses that occur upon shifts in host physiological state.
Molecular correlations across multi-omes
With thousands of multi-omic molecules measured simultaneously 
both in the human host and microorganisms, our study provides 
an opportunity to identify associations between molecules and 
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pathways, and to compare them among insulin-sensitive and insu-
lin-resistant participants. We interpreted associations at two levels 
for healthy visits: the personal level (within-individual by LME mod-
els; Fig. 5, Supplementary Table 30) and at the cohort level (cross- 
sectionally between individuals after correcting for BMI, age and sex; 
Supplementary Table 31), both of which provide different mechanistic 
perspectives (Extended Data Fig. 10a, b).
For intra-individual correlation analyses, we focused on associa-
tions of intra-omes and between gut microorganisms and other host 
omes for differences between insulin-sensitive and insulin-resistant 
groups. We found no significant differences in the average number of 
associations (that is, edges) per analyte between insulin-sensitive and 
insulin-resistant participants. However, insulin-sensitive participants 
had different analyte co-associations (significant, q < 0.05, and unique 
to the insulin-sensitive group) compared to those in insulin-resistant 
participants (Supplementary Table 30), including intra-associations 
among gut microorganisms (Supplementary Table 32). Insulin-
sensitive and insulin-resistant unique and statistically significant asso-
ciations for each gut microorganism are shown in Fig. 5a (pairwise 
association patterns in Extended Data Fig. 10c). Notably, the genus 
Holdemania, which might facilitate cancer immunotherapies35, was 
significantly associated with two other genera (Clostridium.XlVb and 
Phascolarctobacterium, q < 0.05) in insulin-sensitive participants, but 
significantly correlated with five other genera in insulin-resistant par-
ticipants (including Clostridium.XlVa, Clostridium.XVII and Collinsella, 
q < 0.05; Supplementary Table 32). Such insulin-resistant-specific and 
insulin-sensitive-specific associations indicate that there are different 
patterns of gut microbial interactions in the two groups.
We also examined correlations between gut microorganisms and host 
metabolites. The total number of associations differed between insu-
lin-sensitive and insulin-resistant participants, confirming previous 
findings18 (Supplementary Table 33). In the correlations between gut 
microorganisms and host circulating cytokines, we observed five signif-
icant insulin-sensitive-specific associations (q < 0.05) but no insulin- 
resistant-specific associations; for example, the genus Barnesiella 
was positively associated with IL-1β (q = 0.0054) and the genus 
Faecalibacterium was inversely associated with TNFA (q = 0.0244) only 
in insulin-sensitive subjects (Fig. 5b). Because Barnesiella is important 
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Fig. 3 | Dynamics of differential responses during RVI. a, Top, examples 
of the most significantly enriched integrated canonical pathways that 
showed differential changes in response to RVI according to the AUC test 
(two-sided). All P values were corrected using the Benjamini–Hochberg 
(B–H) method for multiple hypothesis correction. The Ingenuity Pathway 
Analysis (IPA) Z-score measures the match between expected relationship 
direction and observed gene expression. The ratio presents the percentage 
of molecules enriched from the total number of molecules within a 
pathway. Bottom, a simplified example of enriched neuroinflammation 
signalling showing molecules that were significantly upregulated (red) 
or downregulated (green) in response to RVI. The full pathway is shown 
in Extended Data Fig. 4d. b, Two time-series clusters (left and middle) 
that show up- and downregulation of significant ’omics molecules during 
RVI (AUC test, two-sided) with their top enriched pathways (black), 
clinical laboratory tests (red), gut microbial communities (green), and 
nasal microbial communities (blue). Trend lines are colour-encoded 
with red shades denoting high membership values of genes belonging to 
the time-series cluster. Right, a general time-series pattern was observed 
regarding viral load in relation to both nasal and gut microbial changes. 
The y axis denotes the percentage of maximal abundance. ALKP, alkaline 
phosphatase; INSU, insulin; INSF, insulin, fasting; LDLHDL, low-density 
to high-density lipoprotein ratio; ALCRU, aluminum/creatinine ratio 
random, urine; BASO, basophil in percentage; RDW, red blood cell 
distribution width; EOS, eosinophil in percentage; CO2, carbon dioxide. 
Virus 1 and Virus 2 denote generically for different viral species that 
changed in individuals. c, Heatmap showing different responses to RVI 
in the insulin-sensitive (77 RVI and 62 healthy categorized time points) 
and insulin-resistant groups (33 RVI and 17 healthy categorized time 
points) at the integrated pathway level based on the AUC test (two-sided) 
over the entire course of RVI and paired t-test (two-sided) for stage-wise 
comparison. Left, B–H corrected pathway P value enrichment heatmap. 
Right, activation Z-score heatmap. Heatmap bottom annotation: AUC, EE, 
EL and RE represent analysis over the entire course of RVI (AUC), at EE, 
EL and RE stages as compared to healthy baseline.
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in host IL-1 activity36 and IFNγ signalling37,38 and Faecalibacterium is 
linked to TNF39, which might synergize with IL-17 activity37,40, the 
lack of these associations in insulin-resistant participants suggests 
that insulin resistance may affect interactions between the gut micro-
biome and host cytokines. Furthermore, the genus Butyricimonas was 
negatively associated with four lipids only in insulin-resistant partici-
pants (q < 0.05, Extended Data Fig. 10d), highlighting this previously 
reported bacterial relationship with lipid metabolism41; our finding 
indicates that this relationship is also relevant to glucose dysregula-
tion. Together, these observations indicate that gut microorganisms and 
host immunity and metabolism are coordinated differently in insu-
lin-sensitive and insulin-resistant participants.
Longitudinal tracking of diabetes in individuals
Analysis of the multi-omic profiles revealed a unique set of molecules 
for each individual that was different from the cohort mean (Fig. 6a, 
Supplementary Table 34). For example, one individual (participant 
number ZJTKAE3) had a high number of outlier transcripts, and 
pathway enrichment analysis suggested that these were enriched in 
toxicity pathways, especially in oxidative stress and hepatic abnor-
mality (Extended Data Fig. 11a, b, Supplementary Table 35). It is 
possible that this individual started to develop hepatic or related 
abnormalities at the molecular level even while symptom-free. 
Indeed, this participant was diagnosed five months later with mild 
hepatic steatosis12.
Longitudinal analysis of another participant (ZNED4XZ) revealed 
a number of ‘healthy’ samples that contained outliers in both metab-
olite and cytokine profiles compared to the rest of cohort (Extended 
Data Fig. 11c, Supplementary Table 36). This participant was clinically 
diagnosed with T2D by an independent hospital 10 months after her 
last study visit, and our data suggest a molecular mechanism of her 
T2D onset. Among a curated list of immune molecules, interleukin-1 
receptor antagonist (IL-1RA) and HSCRP were highly elevated during 
her last three healthy visits before T2D diagnosis (Fig. 6b). Notably, 
262 additional molecules followed the same trend as IL-1RA (and 
75 for HSCRP) along the participant’s path to T2D (Supplementary 
Tables 37, 38). Among molecules that were highly correlated with 
IL-1RA, we found a signature of xenobiotics, including methyluric 
acid and methylxanthine, which are gut microorganism-associated 
metabolites related to impaired glucose tolerance42 (Extended Data 
Fig. 11d). Those xenobiotics were also tightly associated with expres-
sion of host factors involved in the complement system (C4B, C4BPB, 
C4BPA), acute immune response signalling (PIK3CD, MAP3K5), and 
the LPS-stimulated MAPK pathway (RAF1, PRKD3, MAP3K5 and 
PIK3CD; Extended Data Fig. 11d), all of which are associated with the 
development of diabetes43,44. Moreover, we found a decrease in gut 
microbial diversity and weight increase before T2D diagnosis12. Thus, 
by examining multi-omic measurements during the progression to 
T2D, we identified hundreds of molecules in which changes preceded 
the diagnosis of the disease and that are potentially associated with 
mechanisms underlying the development of T2D in this individual. 
Additional examples of health-related discoveries can be found in a 
companion paper12.
Discussion
To better understand how healthy individuals and those at risk of T2D 
change over time and in response to perturbations, we profiled both 
healthy quarterly baselines and other stress visits (for RVI, immuni-
zation, antibiotics and others) for 106 participants over nearly four 
years. This work provides a unique data set that can be used to under-
stand variation both across the cohort and at an individual level among 
healthy baselines and in response to different stresses. For each multi- 
omic measurement, we identified the source of healthy variation and 
studied the variability within and between participants (Supplementary 
Tables 4, 5). Although molecules measured in clinical laboratory tests 
and other omes varied between individuals, overall they were relatively 
stable within each individual. Notably, even though the levels of these 
highly personal molecules may deviate during occurrence of a disease, 
they are still often within the population ‘healthy’ range and thus are 
not diagnosed in an individual using population measurements. The 
strong interpersonal difference among individuals is likely to be the rea-
son why large numbers are required for detecting differences between 
cases and controls in disease studies. The distinct personal baselines 
identified in this study may be due to the genetic, epigenetic, and/or 
environmental (for example, lifestyle, diet preference, exercise level) 
differences between participants.
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Beyond healthy baselines, we examined dynamic changes in host 
molecular pathways and microbiota communities during RVI and 
immunization. During RVI, our integrated multi-omics approach 
revealed activation of defence mechanisms that are associated with 
innate immunity and adaptive responses. Notably, we identified three 
non-respiratory effects that have not been well explored in connection 
to RVI. These include activation of neurological pathways (associated 
with neuroinflammation, Huntington’s disease, and axonal guidance), 
cardiac hypertrophy, and metabolic pathways (for example, insulin 
receptor signalling and leptin signalling in obesity). Multiple epide-
miological and clinical reports have described an association of RVI 
outbreaks with neurological diseases specifically in children, leading 
to an emerging hypothesis that inflammation from respiratory viral 
infections can promote chronic neuronal dysfunction45. The rela-
tion between cardiac complications and RVI is complex. Association 
of cardiac complications with influenza infection in adults has been 
reported46. However, in most of these cases cardiac complication is rel-
atively reversible, as we found in our study. The third extra-respiratory 
effect was on metabolic pathways such as insulin receptor signalling 
and T2D pathways. Although recurrent RVI has been associated with 
type 1 diabetes, this has not been well investigated for T2D except one 
case7; thus, our work extends this observation. As these signatures were 
identified by analysing blood components, they are likely to represent 
systemic effects.
Notably, the insulin-resistant and insulin-sensitive groups differed at 
baseline and during stress responses. Insulin-resistant participants had 
higher triglycerides as well as an increased level of immune molecules, 
consistent with previous findings14,18. Insulin-resistant participants had 
an impaired and delayed response to RVI, and this impairment can 
lead to chronic inflammation resulting in T2D47. In agreement with 
the impaired host response in the insulin-resistant group, nasal and gut 
microbiota in the insulin-resistant group had a milder response to RVI 
than in the insulin-sensitive group. Furthermore, host–microbiome 
associations are affected by insulin-resistance status.
T2D is an inflammatory disease, and several inflammation molecules 
are important indicators of T2D development, including IL-1RA48, 
HSCRP, IL-649, IL-1β and TNF50. In the case of participant ZNED4XZ, 
only IL-1RA and HSCRP increased before the onset of T2D, but not 
the other markers, including IL-6 and IL-1β. Because IL-6 and IL-1β 
are mostly produced by leukocytes in the liver and adipose tissue, it is 
a
b
–0.6
–0.3
0
0.3
0.6
Ak
ke
rm
an
sia
Al
ist
ipe
s
An
ae
ro
tru
nc
us
An
ae
ro
vo
ra
x
Ba
ct
er
oid
es
Ba
rn
es
iel
la
Bi
lop
hil
a
Bl
au
tia
Bu
tyr
ici
co
cc
us
Bu
tyr
ici
m
on
as
Cl
os
tri
diu
m
.IV
Cl
os
tri
diu
m
 se
ns
u 
str
ict
o
Cl
os
tri
diu
m
.X
I
Cl
os
tri
diu
m
.X
lV
a
Cl
os
tri
diu
m
.X
lV
b
Cl
os
tri
diu
m
.X
VI
II
Co
llin
se
lla
Co
pr
oc
oc
cu
s
Do
re
a
Eg
ge
rth
ell
a
Er
ys
ipe
lot
ric
ha
ce
ae
 in
ce
rta
e s
ed
is
Fa
ec
ali
ba
ct
er
ium
Fla
vo
nif
ra
ct
or
Ho
lde
m
an
ia
La
ch
no
sp
ira
ce
a i
nc
er
ta
e s
ed
is
Od
or
iba
ct
er
Os
cil
lib
ac
te
r
Pa
ra
ba
ct
er
oid
es
Pa
ra
su
tte
re
lla
Ph
as
co
lar
ct
ob
ac
te
riu
m
Pr
ev
ot
ell
a
Ps
eu
do
fla
vo
nif
ra
ct
or
Ro
se
bu
ria
Ru
m
ino
co
cc
us
St
re
pt
oc
oc
cu
s
Ba
ct
er
ia 
un
cl.
Cl
os
tri
dia
les
 u
nc
l.
Cl
os
tri
dia
les
 in
ce
rta
e.S
ed
is.
Xi
ii u
nc
l.
Co
rio
ba
ct
er
iac
ea
e u
nc
l.
Er
ys
ipe
lot
ric
ha
ce
ae
 u
nc
l.
Fir
m
icu
te
s u
nc
l.
La
ch
no
sp
ira
ce
ae
 u
nc
l.
Po
rp
hy
ro
m
on
ad
ac
ea
e u
nc
l.
Ru
m
ino
co
cc
ac
ea
e u
nc
l.
Ve
illo
ne
lla
C
or
re
la
tio
n 
co
ef
c
ie
nt
0
5
10
15
20
25
1.2 1.6 2.0 2.4
–4
0
2
2.2 2.4 2.6 2.8
–2
0
2
4
1.2 1.4 1.6 1.8
–4
0
4
2.2 2.3 2.4 2.5 2.6
0
2
4
6
IS
IR
IL-1β
B
ar
ne
si
el
la
q = 0.0054
q = 0.997
q = 0.0244
q = 0.997
Fa
ec
al
ib
ac
te
riu
m
B
ar
ne
si
el
la
IL-1β
Fa
ec
al
ib
ac
te
riu
m
TNFA
TNFA
IS
IR
N
um
b
er of associations
Fig. 5 | Correlational networks capture multi-omics association 
structures that differ between insulin-resistant and insulin-sensitive 
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likely that the development of T2D in this participant was not caused by 
liver or adipose inflammation at those time points. Longitudinal track-
ing and profiling of participant ZNED4XZ demonstrated the power 
to decipher disease aetiology at an individual level, which might be 
more specific than the general understanding gained from population 
measurements. Additional work is required to assess how frequently 
the mechanism we propose in this participant also applies to other 
cases of T2D.
Overall, these results point to a complex and dynamic ’omic land-
scape in both host and microorganisms during health and pertur-
bations such as RVI and immunization. They further reveal how 
insulin-resistant and insulin-sensitive participants differ both at 
baseline and in their responses to RVI. These deep multi-omics meas-
urements enable us to investigate the early molecular signs of disease 
development at an individual level. Future efforts will help to provide 
additional mechanistic understanding of how the multi-omic factors 
affect health and are altered early in disease development, both at the 
cohort and individual levels.
Online content
Any methods, additional references, Nature Research reporting summaries, source 
data, statements of data availability and associated accession codes are available at 
https://doi.org/10.1038/s41586-019-1236-x.
Received: 10 January 2018; Accepted: 16 April 2019;  
Published online 29 May 2019.
 1. Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J. & Kivimäki, M. Prediabetes: 
a high-risk state for diabetes development. Lancet 379, 2279–2290  
(2012).
 2. National Diabetes Data Group Classification and diagnosis of diabetes mellitus 
and other categories of glucose intolerance. Diabetes 28, 1039–1057 (1979).
 3. Bellamy, L., Casas, J. P., Hingorani, A. D. & Williams, D. Type 2 diabetes mellitus 
after gestational diabetes: a systematic review and meta-analysis. Lancet 373, 
1773–1779 (2009).
 4. Pickup, J. C. Inflammation and activated innate immunity in the pathogenesis 
of type 2 diabetes. Diabetes Care 27, 813–823 (2004).
 5. Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 
diabetes. Nature 490, 55–60 (2012).
 6. Gamble, D. R., Kinsley, M. L., Fitzgerald, M. G., Bolton, R. & Taylor, K. W. Viral 
antibodies in diabetes mellitus. Brit. Med. J. 3, 627 (1969).
 7. Mehta, S. H. et al. Prevalence of type 2 diabetes mellitus among persons with 
hepatitis C virus infection in the United States. Ann. Intern. Med. 133, 592–599 
(2000).
 8. Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical 
phenotypes. Cell 148, 1293–1307 (2012).
 9. Integrative HMP (iHMP) Research Network Consortium. The Integrative Human 
Microbiome Project: dynamic analysis of microbiome-host omics profiles 
during periods of human health and disease. Cell Host Microbe 16, 276–289 
(2014).
 10. Buysschaert, M. & Bergman, M. Definition of prediabetes. Med. Clin. North 
America 95, 289–297 (2011).
 11. Greenfield, M. S., Doberne, L., Kraemer, F., Tobey, T. & Reaven, G. Assessment of 
insulin resistance with the insulin suppression test and the euglycemic clamp. 
Diabetes 30, 387–392 (1981).
 12. Schüssler-Fiorenza Rose, S. et al. A longitudinal big data approach for precision 
health. Nat. Med. 25, 792–804 (2019).
 13. Zhou, S. et al. Age-related intrinsic changes in human bone-marrow-derived 
mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 7, 
335–343 (2008).
 14. Abbasi, F., Brown, B. W., Lamendola, C., McLaughlin, T. & Reaven, G. M. 
Relationship between obesity, insulin resistance, and coronary heart disease 
risk. J. Am. Coll. Cardiol. 40, 937–943 (2002).
 15. Reaven, G. M. Role of insulin resistance in human disease. Diabetes 37, 
1595–1607 (1988).
 16. McLaughlin, T. et al. Use of metabolic markers to identify overweight individuals 
who are insulin resistant. Ann. Intern. Med. 139, 802–809 (2003).
 17. Lee, C. T. C. et al. White blood cell subtypes, insulin resistance and β-cell 
dysfunction in high-risk individuals—the PROMISE cohort. Clin. Endocrinol. 81, 
536–541 (2014).
 18. Talukdar, S. et al. Neutrophils mediate insulin resistance in mice fed a high-fat 
diet through secreted elastase. Nat. Med. 18, 1407–1412 (2012).
 19. Piening, B. D. et al. Integrative personal omics profiles during periods of weight 
gain and loss. Cell Syst. 6, 157–170 (2018).
 20. Pallister, T. et al. Hippurate as a metabolomic marker of gut microbiome 
diversity: modulation by diet and relationship to metabolic syndrome. Sci. Rep. 
7, 13670 (2017).
 21. Egshatyan, L. et al. Gut microbiota and diet in patients with different glucose 
tolerance. Endocr. Connect. 5, 1–9 (2016).
 22. Jiang, W. et al. Dysbiosis gut microbiota associated with inflammation and 
impaired mucosal immune function in intestine of humans with non-alcoholic 
fatty liver disease. Sci. Rep. 5, 8096 (2015).
 23. Le Sage, V., Cinti, A., Amorim, R. & Mouland, A. J. Adapting the stress response: 
viral subversion of the mTOR signaling pathway. Viruses 8, 152 (2016).
 24. Kurt-Jones, E. A. et al. Pattern recognition receptors TLR4 and CD14 mediate 
response to respiratory syncytial virus. Nat. Immunol. 1, 398–401 (2000).
 25. Spellberg, B. & Edwards, J. E., Jr. Type 1/type 2 immunity in infectious diseases. 
Clin. Infect. Dis. 32, 76–102 (2001).
 26. Shrestha, N. et al. Eukaryotic initiation factor 2 (eIF2) signaling regulates 
proinflammatory cytokine expression and bacterial invasion. J. Biol. Chem. 287, 
28738–28744 (2012).
 27. Khovidhunkit, W. et al. Effects of infection and inflammation on lipid and 
lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid 
Res. 45, 1169–1196 (2004).
 28. Moon, C. & Stappenbeck, T. S. Viral interactions with the host and microbiota in 
the intestine. Curr. Opin. Immunol. 24, 405–410 (2012).
 29. Groves, H. T. et al. Respiratory disease following viral lung infection alters the 
murine gut microbiota. Front. Immunol. 9, 182 (2018).
 30. Rynda-Apple, A., Robinson, K. M. & Alcorn, J. F. Influenza and bacterial 
superinfection: illuminating the immunologic mechanisms of disease. Infect. 
Immun. 83, 3764–3770 (2015).
 31. Vamos, E. P. et al. Effectiveness of the influenza vaccine in preventing admission 
to hospital and death in people with type 2 diabetes. CMAJ 188, E342–E351 
(2016).
ba
2013 2014 2015 2016 2017
Healthy baseline
VCAM1
IL-1B
TNFB
IL-6
IL-15
IL-8
LIF
TNFA
ICAM1
IL-1A
HSCRP
IL-1RA
H H H H H Im HS H Ax HAx Ax Ax
NA 100 102  98   114 112   97  105 113 112  110 109 110  128 Fasting glucose 
5.8  5.9  5.7   6.0  6.1  5.9  5.7   5.8  5.9  5.8  5.6   5.7  5.9  6.0  A1C
ZKFV71L
ZLTUJTN
ZUG7QHE
ZY9XQJP
ZLGD9M0
ZTXY83G
ZN3TBJM
ZVNCGHM
ZWFDEY0
ZQNZSQF
ZTMFN3O
ZUF48YS
ZPF36E2
ZWLGEWL
ZOBX723
ZY7IW45
ZXHCGKV
ZV14SIB
ZLPRB8E
ZTJ7L7Z
ZYLJ7R7
ZNED4XZ
ZSQNUZ5
ZTL5S2Y
ZNDMXI3
ZUC2YGO
ZMGT937
ZQMVU4Q
ZJTKAE3
ZK4CK8Y
Clinical test Cytokines Microbiome
ProteomeMicrobiome KO
Metabolome
Transcriptome
100 200 300 400 500 0 25 50 75 100
Number of outliers Outlier proportion across ’omes (%)
Fig. 6 | Personal features that precede the onset of T2D revealed 
by longitudinal tracking. a, Left, scatter plot showing the number of 
outliers among thousands of molecules for each participant; right, the 
percentage of outliers contributed by each ome. b, Top, collection timeline 
for participant ZNED4XZ in our study relative to onset of T2D, with green 
arrows pointing to eight healthy baselines (H), purple for one stress visit (S), 
red for four antibiotics visits (Ax) and blue for one immunization visit 
(Im). Bottom, heatmap showing levels of selected immune cytokines 
together with A1C (%) and fasting glucose (mg dl−1) across time. Red 
denotes increased expression; blue represents decreased expression, with 
shades corresponding to levels.
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MEthOdS
Participant recruitment and IRB consent. Participants provided informed 
written consent for the study under research study protocol 23602 approved by the 
Stanford University Institutional Review Board. All participants were studied after 
an overnight fast at the Stanford Clinical and Translational Research Unit (CTRU). 
This study complies with all relevant ethical regulations and informed consent was 
obtained from all participants.
Participants were recruited through placement of advertisements in local news-
papers and radio stations seeking ‘prediabetic volunteers’ at risk of T2D for a lon-
gitudinal multi-omic study. Screening in the CTRU entailed collection of clinical 
history, physical examination, anthropometric measurements, and fasting blood 
tests for exclusions including presence of anaemia defined as haematocrit <30, 
renal disease defined as creatinine >1.5, history of any cardiovascular, malignancy, 
chronic inflammatory or psychiatric disease, and history of any bariatric surgery 
or liposuction. Study survey data were collected and managed using REDCap 
electronic data capture tools hosted at Stanford University.
Each eligible, consented subject underwent one-time quantification of insulin- 
mediated glucose uptake via the modified insulin suppression test as previously 
described and validated10,51. In brief, following an overnight fast, subjects were 
infused for 180 min with octreotide (0.27 µg/m2 min), insulin (25 mU/m2 min), 
and glucose (240 mg/m2 min). Blood was drawn at 10-min intervals from 150 to 
180 min of the infusion to measure plasma glucose (oximetric method) and insulin 
(radioimmunoassay) concentrations: the mean of these four values comprised the 
SSPG and insulin concentrations for each individual. At steady state, insulin con-
centrations (65 µU/ml) were similar in all subjects and the SSPG provides a direct 
measure of the relative ability of insulin to dispose of a glucose load: the higher the 
SSPG concentration, the more insulin-resistant the individual. While the SSPG is 
distributed continuously, for the purpose of this study, we defined insulin-sensitive 
as SSPG < 150 mg/dl and insulin-resistant as SSPG ≥ 150 mg/dl, largely to provide 
separation between the two groups. In some cases SSPG tests were not performed, 
for reasons including: 1) participants withdrew from the study before their scheduled 
tests; 2) participants opted out of (that is, did not consent to) this test owing to their 
own schedule conflicts or other personal reasons; 3) participants were not eligible 
for the test as were already diagnosed as having diabetes (the IRB will not allow this).
Blood sample preparation. Blood was drawn from overnight-fasted participants 
at the indicated time points at the Stanford CTRU. An aliquot of blood was incu-
bated at room temperature to coagulate; clots were subsequently pelleted and the 
serum supernatant was pipetted off and immediately frozen at –80 °C. Blood from 
separate EDTA tubes was immediately layered onto Ficoll medium and spun via 
gradient centrifugation. The top layer of plasma was pipetted off, aliquoted and 
immediately frozen at –80 °C. The PBMC layer was removed and counted using 
a cell counter, and aliquots of PBMCs were further pelleted and flash-frozen with 
DMSO/FBS. For the subsequent multi-omic analyses, PBMCs were thawed on ice, 
and subsequently lysed and processed to DNA, RNA and protein fractions using 
Allprep Spin Columns (Qiagen) according to the manufacturer’s instructions and 
using the Qiashredder lysis option. Plasma analysis was performed on individual 
aliquots to prevent freeze–thaw cycles.
Exome sequencing. In brief, DNA was isolated from blood using Gentra Puregene 
Kits (Qiagen) according to the manufacturer’s instructions. Exome sequencing 
was performed in a CLIA- and CAP-accredited facility using the ACE Clinical 
Exome Test (Personalis). Variant calling was performed using an in-house devel-
oped automated pipeline52.
RNA sequencing. The transcriptome was evaluated using RNA-seq of bulk 
flash-frozen PBMCs. We used Qiagen All prep kit to extract total RNA from PBMCs 
according to the manufacturer’s protocol. The RNA libraries were constructed using 
the TruSeq Stranded total RNA LT/HT Sample Prep Kit (Illumina) with 500 ng 
total RNA, according to the manufacturer’s instructions. In brief, ribosomal RNA 
was depleted from total RNA using Ribo-Zero magnetic beads, then the ribosomal 
RNA-depleted RNA was purified and fragmented. A random primer tailed with 
an Illumina adaptor was used to perform reverse transcription to obtain a cDNA 
library. An adaptor sequence was added to the other end of the cDNA library with 
a Terminal-Tagging step. The cDNA library was amplified using the Illumina prim-
ers provided with this kit. Liquid handling was performed with an Agilent Bravo 
Automated Liquid Handling Platform. RNA-seq libraries were sequenced using the 
Illumina HiSeq 2000 (Illumina) instrument per the manufacturer’s instructions. 
Each library was quantified using an Agilent Bioanalyzer and Qubit Fluorometric 
quantification (ThermoFisher) using a dsDNA high-sensitivity kit. Quantified, bar-
coded libraries were normalized and mixed at equimolar concentrations into a mul-
tiplexed sequencing library. Sequencing of libraries was performed up to 2 × 101 
cycles. We sequenced on average 5–6 libraries per lane of HiSeq2000. Image analysis 
and base calling were performed with the standard Illumina pipeline.
The TopHat package53 was used to align the reads to the hg19 reference genome 
and personal exome, followed by HTseq and DESEQ2 for transcript assembly and 
quantification of RNA expression54,55. Custom scripts in R and Python were used 
for downstream analyses. For data preprocessing, we first removed genes with 
average read counts over all samples smaller than 0.5. Then, samples with average 
read counts over all filtered genes smaller than 0.5 were filtered out.
The input file contained 883 samples as columns and 25,364 genes as rows. 
After filtering steps, we had 883 samples with expression data from 13,379 genes. 
For global variance and correlation analyses, in order to reduce the number of 
features, we removed genes with average read counts less than 1, resulting in 
10,343 genes. We also used the xCell algorithm56 to deconvolute PBMC cell types 
based on RNA-seq data. For computation of abundance scores with xCell, all 
gene expression data were concatenated into a single file. Abundance scores were 
then computed from the expression data using xCell (xCellAnalysis function run 
with the ‘rnaseq =TRUE’ option and N = 64). The abundance scores of PBMC 
deconvoluted cell types were then used to classify stress events.
Microbiome sampling. Sampling of stool, nasal, tongue and skin microbiomes 
was conducted according to the Human Microbiome Project – Core Microbiome 
Sampling Protocol A (https://www.hmpdacc.org/). Once samples were received in 
the laboratory, they were subsequently stored at –80 °C until further processing.
Microbiomics. DNA extraction. DNA extraction was performed following Human 
Microbiome Project – Core Microbiome Sampling Protocol A (HMP Protocol # 
07-001, v12.0). Metagenomic DNA was isolated in a clean hood using the MOBIO 
PowerSoil DNA Extraction kit, with added proteinase K, followed by lysozyme and 
staphylolysin treatment.
Targeted rRNA gene amplification and sequencing. For 16S (bacterial) rRNA gene 
amplification, hyper-variable regions V1–V3 of 16S were amplified from the 
metagenomic DNA using primers 27F and 534R (27F:5′-AGAGTTTGATCCTGGC 
TCAG-3′ and 534R: 5′- ATTACCGCGGCTGCTGG-3′). The oligonucleotides con-
taining the 16S primer sequences also contained an adaptor sequence for the Illumina 
sequencing platform. A barcode sequence unique to each sample was embedded 
within each of the forward and reverse oligonucleotides used to create the amplicons 
(dual tags). The uniquely barcoded amplicons from multiple samples were pooled and 
sequenced on the Illumina MiSeq sequencing platform using a V3 2 × 300 sequencing 
protocol. The 16S rRNA gene is about 1.5 kb, and includes nine variable regions that 
provide much of the sequence distinction between different taxa. Variable regions 1–3 
are generally sufficient to identify taxa down to the genus level, and sometimes to the 
species level. Illumina’s software handles the initial processing of all the raw sequencing 
data. One mismatch in primer and zero mismatch in barcodes were applied to assign 
read pairs to the appropriate sample within a pool of samples. Barcodes and primers 
were removed from the reads. Reads were further processed by removing sequences 
with low quality (average qual <35) and ambiguous bases (Ns). Chimeric amplicons 
were removed using UChime, and amplicon sequences were clustered and operational 
taxonomic units (OTU) picked by Usearch against GreenGenes database (May 2013 ver-
sion). Final taxonomic assignment was performed using RDP-classifier. All details were 
executed using QIIME57 with custom scripts.
Metagenomic shotgun sequencing. DNA was also subject to whole genome metagen-
omic shotgun sequencing (mWGS) for a selection of nasal swabs during infection 
to identify bacteria and viruses to the species level (described in more detail in 
an accompanying paper39). The libraries were prepared according to a standard 
protocol from Illumina, and at least 1 Gb of 150 bp pair-end reads per sample was 
sequenced on the Illumina HiSeq or MiSeq instrument. Downstream process-
ing of the mWGS reads included a) identification and masking of human reads 
(using NCBI’s BMTagger, ftp://ftp.ncbi.nlm.nih.gov/pub/agarwala/bmtagger); 
b) removal of duplicated reads that are artefacts of the sequencing process; 
c) trimming low-quality bases; and d) low-complexity screening (b–d were done 
through PRINSEQ). Reads trimmed to less than 60 bp were removed and the 
remaining high-quality reads were analysed downstream.
Untargeted metabolomics by LC–MS. Plasma samples were prepared and 
analysed in a randomized order as previously described58. In brief, metabolites 
were extracted using 1:1:1 acetone:acetonitrile:methanol, evaporated to dryness 
under nitrogen and reconstituted in 1:1 methanol:water before analysis. Metabolic 
extracts were analysed four times using hydrophilic interaction (HILIC) and 
reverse-phase liquid chromatography (RPLC) separation in both positive and 
negative ionization modes. Data were acquired on a Thermo Q Exactive plus mass 
spectrometer for HILIC and a Thermo Q Exactive mass spectrometer for RPLC. 
Both instruments were equipped with a HESI-II probe and operated in full MS scan 
mode. MS/MS data were acquired on quality control samples (QC) consisting of an 
equimolar mixture of 150 randomized samples from the study. HILIC experiments 
were performed using a ZIC-HILIC column (2.1 × 100 mm, 3.5 µm, 200 Å; Merck 
Millipore) and mobile phase solvents consisting of 10 mM ammonium acetate in 
50/50 acetonitrile/water (A) and 10 mM ammonium acetate in 95/5 acetonitrile/
water (B). RPLC experiments were performed using a Zorbax SBaq column (2.1 × 
50 mm, 1.7 µm, 100 Å; Agilent Technologies) and mobile phase solvents consisting 
of 0.06% acetic acid in water (A) and 0.06% acetic acid in methanol (B).
Metabolomics data processing. Metabolic extracts from 979 samples were prepared 
in a randomized order and data were acquired in three batches. LC–MS data were 
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processed using Progenesis QI (Nonlinear Dynamics). Metabolic features from 
blanks and that did not show sufficient linearity upon dilution were discarded. 
Only metabolic features present in >33% of the samples were kept for further 
analysis and missing values were imputed using the k-nearest neighbours method. 
MS signal drift with time for non-targeted data cannot be easily corrected by using 
a small number of internal standards, as the drift is nonlinear and metabolite- 
dependent. To circumvent this issue, we applied LOESS (locally estimated scatter-
plot smoothing) normalization to our data. Each metabolic feature signal drift with 
time was independently corrected by fitting a LOESS curve to the MS signal meas-
ured in QCs. QCs were injected every 10 biological samples and consisted of an 
equimolar mixture of 150 random samples from the study. We showed that LOESS 
normalization was efficient to correct intra- and inter-batch metabolite-specific 
signal drifts as in Extended Data Fig. 1e. After further pre-processing and anno-
tation of the metabolic features, a total of 722 metabolites were measured using 
our metabolite profiling platform, among which 431 were identified by matching 
retention time and fragmentation spectra to authentic standards or by comparing 
fragmentation spectra to public repositories.
Proteomics (SWATH-mass spectroscopy). Tryptic peptides of plasma samples 
were separated on a NanoLC 425 System (SCIEX). The flow was 5 µl/min with 
trap-elute setting using a 0.5 × 10 mm ChromXP (SCIEX). The LC gradient was 
set to a 43-min gradient from 4–32% B with 1 h total run. Mobile phase A was 
100% water with 0.1% formic acid. Mobile phase B was 100% acetonitrile with 0.1% 
formic acid. We used an 8-µg load of undepleted plasma on a 15-cm ChromXP 
column. MS analysis was performed using SWATH acquisition on a TripleTOF 
6600 system equipped with a DuoSpray source and 25-µm ID electrode (SCIEX). 
Variable Q1 window SWATH Acquisition methods (100 windows) were built in 
high-sensitivity MS/MS mode with Analyst TF Software 1.7.
Proteomics data processing. Peak groups from individual runs were statistically 
scored with pyProphet59 and all runs were aligned using TRIC60 to produce a final 
data matrix with 1% FDR at peptide level and 10% FDR at protein level. Protein 
abundances were computed as the sum of the three most abundant peptides (top3 
method). A major maintenance of the mass spectrometer caused considerable batch 
effects across measured samples. To reduce batch effects, we performed subtraction 
of the principal components showing a major batch bias using Perseus61 1.4.2.40.
Luminex assays. Levels of circulating cytokines in the blood were measured using 
a 63-plex Luminex antibody-conjugated bead capture assay (Affymetrix) that has 
been extensively characterized and benchmarked by the Stanford Human Immune 
Monitoring Center (HIMC). Human 63-plexes were purchased from eBiosciences/
Affymetrix and used according to the manufacturer’s recommendations with mod-
ifications as described below. In brief, beads were added to a 96-well plate and 
washed using a Biotek ELx405 washer. Samples were added to the plate containing 
the mixed antibody-linked beads and incubated at room temperature for 1 h fol-
lowed by overnight incubation at 4 °C with shaking. Cold and room-temperature 
incubation steps were performed on an orbital shaker at 500–600 r.p.m. After the 
overnight incubation, plates were washed using a Biotek ELx405 washer and then 
biotinylated detection antibody added for 75 min at room temperature with shak-
ing. The plate was washed as above and streptavidin-PE was added. After incuba-
tion for 30 min at room temperature, a wash was performed as above, and reading 
buffer was added to the wells. Plates were read using a Luminex 200 instrument 
with a lower bound of 50 beads per sample per cytokine. Custom assay control 
beads by Radix Biosolutions were added to all wells. Results from different batches 
were further corrected using controls and replicates shared between batches. 
The assay was performed by Stanford HIMC.
Multivariate data analysis. Data matrices from all ’omics (clinical laboratory test, 
cytokines, transcriptome, MS-based proteome, metabolome, microbiome 16S data 
and WGS) were obtained and processed into a common format. Metabolites and 
protein MS intensities were log-transformed, while transcripts read counts were 
log2(n + 1) transformed. Only microbial taxa that were present (>0) or microbial 
genes with >0.1% abundance in more than a half of the entire collection (>400) 
were used further for downstream analysis. Microbial taxa and genes were arcsine 
transformed for downstream linear analyses62,63. Analyses for generating reported 
results are further specified below.
Cohort interquartile range (IQR) and individual IQR. To evaluate the dispersion 
pattern of values per analyte across the whole cohort and within each subject, we 
used IQR to describe this variation. Analytes were first standardized with a stand-
ard deviation of 1 centred at 0 before applying IQR(Exp, na.rm = TRUE, type = 8) 
from the R stats package, where Exp was the linearly transformed and standardized 
values of each analyte. Values from all healthy visits of the entire cohort regardless 
of subjects were used to calculate the cohort IQR while only healthy visits of the 
corresponding subject were used for that individual’s IQR. The density plots of IQR 
distribution for each ’ome were visualized by geom_density() in R ggplot2 package.
Healthy baseline variance decomposition. As each subject was sampled repeat-
edly at healthy visits, we used LME models to account for this dependence within 
subjects. We modelled random intercepts but a fixed slope, allowing different 
personal levels between subjects. We first linearly transformed each analyte (when 
applicable) and standardized the total variation to 1 before applying lmer() func-
tion from ‘lme4’ R package, with formula as: lmer(Exp ~ 1 + Days + A1C + SSPG 
+ FPG + (1|SubjectID), data = data set, REML = FALSE), in which Exp was the 
linearly transformed and standardized values of each analyte. We thereby used 
intra-class correlation (ICC) as the proportion of total variation explained by sub-
ject structure in the cohort by Vrandom subject/Vtotal, in which V was variance 
from the corresponding component extracted by VarCorr() and Vtotal was 1. Variations 
explained by fixed factors (Days, A1C, SSPG and FPG) were extracted by anova().
Healthy MDS profiles influenced by personal factor. Either top ’omic mol-
ecules with the most individual contribution (highest in ICC) or molecules 
from each ’ome were used for further multidimensional scaling (MDS) analysis. 
The distance among healthy visits were calculated using Manhattan method in 
metaMDSdist() function from R vegan package and the MDS analysis using 
metaMDS() with k = 2. We calculated an individuality score (ind_score) by 
using the median value of healthy baselines in each individual and averaging 
pairwise distance among all individuals across molecules in question. Therefore, 
a higher ind_score and thus a larger average distance indicates a more distinct 
inter-personal pattern.
Associations with time. We first used the first healthy visit as the reference baseline 
for each subject. The delta changes in the expression values in subsequent healthy 
visits were used to correlate with the delta change in days. Healthy visits from 
subjects with at least three healthy visits were used to assess the time associations. 
As each subject was sampled repeatedly at healthy visits, we used LME models to 
account for this dependence within subjects. We used rmcorr64, a method that 
is close to a null multilevel model of varying intercept and a common slope for 
each individual, and specifically tests for a common association between variables 
within each subject. Rmcorr calculates an effect size to appropriately represent the 
degree to which each subject's data are reflected by the common slope of the best-
fit parallel lines. The rmcorr method takes meta-analytic approach and calculates 
rrm (error degrees of freedom), P value (determined by the F-ratio: F(Measure 
df (1), Error df)), and a 95% confidence interval of effect sizes (95% CI). When 
the relationship between variables varies widely across subjects, the rmcorr effect 
size will be near zero with confidence intervals also around zero. When there is 
no strong heterogeneity across subjects and parallel lines provide a good fit, the 
rmcorr effect size will be large, with tight confidence intervals. Additionally, to 
avoid potential bias introduced by subjects who had too few baseline profiles, 
analyses were also performed using a subset of 27 subjects who had more than 
900 days profiled to compare. rrm correlation was further corrected for multiple 
hypothesis testing by FDR.
Associations with SSPG or difference between insulin-resistant and insulin- 
sensitive in healthy baseline. We used between-individual correlation approach 
for this (see ‘Correlation network analysis’ section below). The median values of 
all healthy baselines per subject were used to associate their SSPG values or to 
compare insulin-resistant with insulin-sensitive results. Pearson correlation was 
used after linear transformation, normalization and correction for BMI, age and 
sex using the R ppcor package. For insulin-resistant/insulin-sensitive correlation, 
insulin-resistant/insulin-sensitive classification was first applied as dummy 
variables (insulin-sensitive as 0, insulin-resistant as 1) before further analyses. 
Additionally, with the method correcting BMI, age and sex, we tested the correla-
tion with potential confounding factors, such as HDL, triglycerides, and triglyc-
erides/HDL ratio, with SSPG10,15 as well as medication status on statin and any 
glucose control medication.
’Omics differential signatures during stress events. In order to identify 
temporal changes in ’omics molecules that deviated from the personal baseline 
over the course of stress events, we implemented the area under the curve 
(AUC) test. We defined longitudinal categories as follows: pre-healthy (–H) state 
(healthy baselines within 186 days before the event’s onset), event early (EE) state 
(visits on days 1–6 of the event), event late (EL) state (visits on days 7–14 since 
the event started), recovery (RE) state (visits within days 15–40 since the event 
started), and finally post-healthy (+H) state (visits within 186 days after the event; 
Fig. 3a).
The AUC test calculates the sum of means of each group (EE, EL, RE) after 
personal baseline correction, where the variation of the correction was also taken 
into account. As its name indicates, the AUC corresponds to area under the curve 
during the stress response over the five categorized time points (–H, EE, EL, RE, 
+H). This quantity can be interpreted as the total amount of change in the expres-
sion or abundance of molecules that deviate from the personal baseline over the 
entire course of RVI or immunization.
For each ’omics feature, the null hypothesis is that the mean expression level 
remains the same over the course of RVI or immunization. Under the null hypoth-
esis, for each stress event we assume:
µ σα ~X N ( , )i i,
2
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for individual i and category α∈{EE, EL, RE}. That is, the mean expression level 
depends on the individual but does not depend on the event type. For each sample 
with an event category Xi,α, α{EE, EL, RE}, the personal baseline is corrected by 
subtracting the mean of the healthy time points next to it (within the 186-day 
window). Let the corrected sample be ∼ αXi,  and ∼αmean  be the mean of the corrected 
samples in group α. We use the following testing statistics:
=
∑
∼
∼
α αAUC
mean
std
where ∼std is calculated by keeping track of the weights for each samples so that 
AUC~N(0, 1) under the null hypothesis. Then the P values can be calculated 
accordingly.
Moreover, we compared the AUC performance with one of the standard meth-
ods for longitudinal analysis, that is, linear regression (LR) analysis with the time 
covariate. We used the standard LR analysis using the python implementation 
(statsmodel.OLS)65. We used time as a real valued covariate and the individual ID 
as a categorical covariate. Both AUC and LR methods performed well in identifying 
differentially expressed molecules (Extended Data Fig. 4a). While more than half of 
features identified by the LR method as differentially expressed molecules were also 
found by the AUC method (that is, 53% for RNA-seq), the AUC method identified 
more features than the LR method (Extended Data Fig. 4a). We therefore used the 
AUC test for our differential expression/abundance analyses over the stress events.
In order to assess differential changes per each event category (that is, only EE 
versus personal baseline), we used the paired t-test. The choice of paired t-test was 
to standardize the analysis across all different types of ’omics data. We performed 
the AUC test and paired t-test on pre-processed data, including transcriptome, 
metabolome, proteome, cytokine, r16S gut microbiome, r16S nasal microbiome, 
microbial predicted genes (KO genes by KEGG), and clinical laboratory test data. 
Transcriptome data were normalized according to size factor and converted into the 
log space by log(Xij + 0.5) for downstream analyses. For size factor correction, first 
the geometric mean of each gene expression across all samples was calculated. The 
size factor for each sample is the median across genes of the ratio of the expression to 
the gene’s geometric mean. Then the read counts for each sample were normalized by 
the size factor. The size factor correction was carried out as described in DESeq255,66.
We used q-values for false discovery rate control. We considered molecules 
with q < 0.1 to be significant. It is of note that for stage pairwise comparisons 
(for example, EE versus personal healthy baseline), we compared the performance 
of the paired t-test with the DESeq2 method for differential analyses of transcrip-
tome data (Extended Data Fig. 4b, Supplementary Table 39). The number of dif-
ferentially expressed transcripts (q < 0.1) identified by paired t-test was 6,857 
and the number of differentially expressed transcripts (q < 0.1) identified by the 
DESeq2 method was 4,062, of which 71% overlapped with paired t-test results 
(Extended Data Fig. 4b). Moreover, pathway enrichment analyses for differen-
tially expressed transcripts by both methods showed the same pathway enrichment 
results (Supplementary Table 40). Because the difference between results obtained 
from the paired t-test and Deseq2 methods for transcripts was minor, we decided 
to use the paired t-test for our analyses in order to standardize the analysis across 
all different types of ’omics data.
We applied ingenuity pathway analysis (IPA)67 to search for enriched pathways 
in our list of differentially expressed ’omics molecules. For integrated canonical 
pathway analysis, the significant transcripts, proteins, metabolites and cytokines 
were combined and used as an input file along as their respective P values and AUC 
statistics. The AUC statistic is used by IPA for generating pathway activity z-scores 
to predict activation or inhibition of enriched pathways. For event category analysis 
(that is, only EE versus personal baseline), we used paired t-test P values of signif-
icant ’omics molecules and log2(baseline normalized read counts) for changes in 
expression or abundance as input for IPA analyses. The IPA enrichment algorithm 
uses two scores that addresses two independent aspects of the analyses. The first is 
the ‘enrichment’ score based on Fisher’s exact test P value. The P value represents 
the significance of the overlap between observed and predicted regulated mole-
cules. The second score is the activation Z-score, which is a prediction measure-
ment for the activation or inhibition state of the regulators in the pathways. Please 
note that the activation Z-score value of zero for pathways that have significant 
P values means that the IPA algorithm could not predict the activation or inhibition 
of the pathway and regulators67.
Furthermore, in order to uncover trends in statistically significant (AUC test 
q < 0.1) ’omics responses to stress events, we used longitudinal pattern recogni-
tion using fuzzy c-means68 clustering across all the data. We first used the elbow 
method to identify the optimal number of clusters in our data set. Data from the 
transcriptome, proteome, metabolome, cytokines, clinical laboratory tests and 16S 
gut and 16S nasal microbiomes, as well as microbial KO genes, were standardized 
to Z-scores for each analyte and subjected to c-means clustering over the course 
of RVI or immunization. Each subplot in Extended Data Figs. 5, 6 shows a unique 
cluster and is colour coded on the basis of correlation membership scores. The top 
integrated canonical pathways (transcripts, proteins, metabolites, cytokines), and 
the trends for the top other analytes (microbiome and clinical laboratory tests) 
are shown above each plot.
Classification of stress events. In order to predict stress events (that is, RVI versus 
healthy time points), we tested multiple models, of which the LR and the SVM 
performed best. Two predictions were executed: 1) healthy baselines versus RVI 
(Fig. 4c, Extended Data Fig. 8), and 2) healthy baselines versus immunization 
(Extended Data Fig. 9).
Data preparation. We used eight sets of data: transcriptome, cytokines, metabo-
lome, proteome, r16S gut microbiome, r16S nasal microbiome, PBMC deconvo-
luted cell types, and clinical laboratory test data. For the transcriptome data, we 
applied VST (variance stabilization transformation) from the DeSeq2 algorithm55 
and used a subset of genes that are immune-related based on previous studies56 
(Supplementary Table 27). For cytokines, metabolome, proteome and r16S data, 
we corrected for the size factor. Features with more than 100 missing values were 
discarded. Also, healthy time points with HS-CRP values larger than 10 were 
discarded. The feature HS-CRP was not used for prediction, as we already used 
this information to filter out samples. Finally, we applied Z-transformation to all 
features so that they had means of 0 and variances of 1 (across the time points).
We executed LR and SVM for our prediction models, as implemented in python 
package sklearn. For both methods, l1 regularization is used to encourage the 
sparsity of the learned coefficient. Two prediction experiments were performed: 
healthy versus RVI, and healthy versus immunization. We only used the infection 
and immunization time points close to the onset of RVI (EE and EL groups). 
The prediction performance was evaluated by receiver operating characteristic 
(ROC) curves and areas under the ROC curve (AUC) for every ’ome (transcrip-
tome, metabolome, proteome, cytokines, PBMC cells types, r16S gut microbial 
taxa, r16S nasal microbial taxa and clinical laboratory tests) and also of all ’omes 
combined (or multi-omes). The ROC plot shows true positive rate (TPR) against 
false positive rate (FPR). The curve was calculated by varying the decision thresh-
old to have different TPR–FPR tradeoffs.
For every experiment, we randomly selected 70% of data for the training set 
and 30% of data for the testing set. Time points from the same individual were 
used in only one of the two sets. This was repeated 100 times. The regularization 
parameters were selected based solely on the training set, as follows. For each reg-
ularization parameter C over the set [0.1, 0.5, 1, 2, 3, 5, 10], the training data were 
further split into train_train and train_test. A classification model (LR or SVM) 
was trained on train_train and evaluated on train_test. This was done five times 
and the regularization parameter with the smallest error on train_test was chosen 
as the optimal parameter. Then, the model was trained with the entire training set 
and the optimal regularization parameter, and evaluated on the testing set.
Correlation network analysis. Given the Simpson’s paradox in correlational anal-
yses (wherein trends can disappear or reverse when data sets are combined)69, 
we used two statistical approaches to investigate between-individual and within- 
individual correlations separately, as these reveal different perspectives in under-
standing the associations.
Within-individual correlations (at the personal level). This takes all the healthy vis-
its per subject into account, and used linear mixed effect models to account for 
repeated samplings from the same subject. We used the rmcorr method64, which 
is close to a null multilevel model of varying intercept and a common slope for 
each individual, and specifically tests for a common association between variables 
within each subject. Healthy visits were first grouped into insulin-sensitive and 
insulin-resistant, and each analyte was linearly transformed before applying the 
rmcorr() function from the rmcorr R package as explained above (see ‘Associations 
with time’). As this method relies on repeated measures within each subject and 
specifically tests for a common association between variables within each subject, 
potentially confounding factors between subjects, such as sex, age and BMI, do not 
apply, which is in contrast to the between-individual correlation method below.
Between-individual correlations (at the cohort level). This first takes the median 
value of all healthy visits per subject, linearly transforms and then corrects for sex, 
age and BMI before applying the regression pcor.test() function from the ppcor R 
package. As this method replies on the median value of repeated measures within 
each subject, those become independent observations presenting different subjects, 
so this is suitable for standard linear regression methods downstream.
P values obtained from the above two approaches were further multiple hypoth-
esis corrected by the total number of pairwise comparisons using the FDR method 
as implemented by p.adjust(p.value, method = “fdr”) in R. We used q < 0.05 as the 
significant cutoff for all ’omic analytes.
For microbiome-related networks, we implemented two approaches to construct 
a correlational network that accounts for the compositionality effect. In the first 
approach, we used centered log ratio (CLR)70 as a preprocessing transformation 
method that addresses compositionality in microbial data71. Given a sample with 
D taxa, the CLR transformation can be obtained as follows:
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Because microbial taxa span different taxonomic levels (phylum, class, order, 
family, genus), we used CLR transformation on each taxonomic level separately. 
After accounting for compositional effect via CLR transformation, we addressed 
the intra-personal correlation of repeated measurements in the calculation of 
correlation coefficient between taxa by using repeated measures correlation 
(rmcorr) method64. Hence, by using this approach, we accounted for composi-
tional effects via CLR and repeated measurements via rmcorr (CLR + rmcorr). For 
all microbiome–host networks (Fig. 5c, d), we used this approach to calculate the 
correlation to host ’omics (transcriptomics, proteomics, metabolomics, cytokines, 
and clinical data).
In the second approach, we used SparCC72 to construct a microbial–microbial 
network over repeated measurements73 (Fig. 5a, b). We used the python imple-
mentation of SparCC in https://bitbucket.org/yonatanf/sparcc with parameters: 
–iter = 20,–xiter = 10,–threshold = 0.1. Also, we obtained the P value for each cor-
relation coefficient by bootstrapping the data set 100 times and applying SparCC 
to each of those 100 data sets. We applied SparCC to features from each taxonomic 
rank separately to avoid correlations between parent and child taxa. We further 
compared the microbiome–microbiome network calculated either by SparCC or 
by CLR+rmcorr (Supplementary Table 32). Correlation coefficients obtained by 
either method were linearly associated, and more than 50% of significant cor-
relations overlapped, indicating that both methods generally agree. However, 
some correlations were detected by only one method. Future studies are needed 
to improve the microbial correlation techniques, as also suggested previously73.
Outlier analysis. To account for healthy baseline variability, only subjects with at 
least three healthy visits were included in the analysis. Z-scores were calculated for 
each analyte after log2-transformation using the median value among healthy visits 
for each subject. Outliers were defined as being in the 95th percentile of Z-score 
distribution for each analyte. The outlier proportion across assays was calculated 
by normalizing the number of outliers from each assay to the total number of 
analytes profiled with the corresponding assay. The percentage of outlier analytes 
across assays in each participant was then normalized to 100%. Analytes with more 
than 50% of missing values or zeros were discarded. For transcriptomics data, we 
arbitrarily chose to discard genes with low expression (log2 normalized read count 
<5 in more than 50% of the subjects).
While providing tremendous amounts of molecular information, our study 
has several limitations that necessitate future investigation. First, it is possible that 
protein isoforms and/or transcript variants are also critical for accurately evaluating 
host states, which were not examined in the current study. Our studies of micro-
bial changes are also limited, as microbial profiles are based on 16S sequencing, 
which only allows taxonomy assignments at the genus level and thereby limits more 
precise interpretations requiring species or strain classifications. Second, as our 
study is observational, samplings in our study are both planned (most healthy 
visits) and spontaneous (some healthy visits and most stress visits), resulting in 
uneven collections. In addition, we utilized a variety of techniques to profile dif-
ferent molecules, so each type of data set has its inherent errors specific to its cor-
responding platforms. As such, our data are heterogenous by nature, and require 
custom and novel methods that statistically account for many sources of variation. 
Our analyses here tend to account for some sources of variation, but additional 
methods are necessary for future work. Last, we only considered BMI, age and 
sex as the universal confounding factors in the current study for our correlational 
analyses. However, there may be additional factors, such as diet and exercise, that 
need to be considered. For instance, in our analysis of age associations, we cannot 
exclude the possible influence of changes in lifestyle over the profiling period. 
Nonetheless, as our cohort is currently expanding to include more participants 
with continuing longitudinal samplings and archived biobanked collections, we 
believe it will provide a rich and valuable resource for future research both exper-
imentally and informatically.
Reporting summary. Further information on research design is available in 
the Nature Research Reporting Summary linked to this paper.
Data availability
Raw data included in this study are hosted on the NIH Human Microbiome 
2 project site (https://portal.hmpdacc.org) with no restrictions on its use. Exome 
sequencing data are also available at dbGaP under Study Accession phs001719.
v1.p1. Both raw and processed data are also hosted on the Stanford iPOP site 
(http://med.stanford.edu/ipop.html).
Code availability
Available data and tools were developed as open source, with CC0 for data and 
MIT for software as open-source licenses. Processed data and custom analysis 
scripts are hosted on the Stanford iPOP site (http://med.stanford.edu/ipop.html).
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Extended Data Fig. 1 | Summary of visits sampled and technical 
normalization across the study. a, Visit chart along the time axis 
illustrated for each subject. b, Number of healthy baselines across the study 
per subject. c, Number of event visits (top, RVI; bottom, immunization) 
since the onset of events. Visits with defined days from onset of events 
were counted. d, Comparison of before and after normalization of 
cytokine data in order to correct batch effects during the assay. The after-
normalization data show overall reduced coefficient of variation (CV).  
Red line, 25% CV. An example is shown for correcting five samples from 
two batches. e, Comparison of before (left) and after (right) LOESS 
normalization of metabolite data using l-lysine as an example. l-Lysine 
signal drift with time was independently corrected by fitting a LOESS 
curve to the l-lysine signal measured in QCs. QCs were injected every ten 
biological samples and consisted of an equimolar mixture of 150 random 
samples from the study. Red, l-lysine signals from QCs; green, biological 
samples in HILIC ESI(+) MS mode.
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Extended Data Fig. 2 | Variance among healthy baselines (n = 624) 
observed for each measurement. a, Examples of measurements with 
their normalized values and corresponding IQR either outlined by 
boxes or quantified by numbers below. b, Scatter plots show diverse 
association patterns between IQR and expression or abundance level for 
measurements across all healthy visits in different ’omes. c, Scatter plots 
of gut and nasal mean abundance versus corresponding ICC for each 
measurement across all healthy baselines. Each measurement is presented 
as one grey dot; darkness of grey reflects the degree of overlap of nearby 
dots. d, MDS plots for each ’ome. MDS1 and MDS2 were shown as the  
x and y axis, respectively. Only 14 subjects with at least ten healthy 
baselines were used for plotting to achieve clear visualization of the 
clustering patterns. Subjects were given the same colour code across plots. 
Individual separation scores (Ind_score) calculate the average distance 
between any two individuals across all analytes in each ’ome.
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Extended Data Fig. 3 | Factors that contributed to the variance among 
healthy baselines. a, b, Examples of measurements correlated with the 
day factor in our study. Rmcorr correlation is used for the association 
calculations. a, The association between the level of ALKP and the 
day factor was significant both in all 106 subjects and in 27 subjects 
sampled for more than 900 days. b, The association between the level of 
pregnenolone sulfate and the day factor was significant only in 27 subjects 
sampled for more than 900 days but not when all 106 subjects were 
included. Individuals were coloured differently for comparison. c, The 
expression pattern of measurements that differed significantly between 
insulin-resistant (n = 35, red) and insulin-sensitive (n = 31, green) 
subjects in healthy baselines (Wilcoxon-rank test, two-sided).  
On the left: pink, clinical laboratory tests; grey, metabolites; dark  
green, gut microorganisms.
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Extended Data Fig. 4 | See next page for caption.
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Extended Data Fig. 4 | Differential responses to RVIs. a, Comparison 
of AUC test (two-sided) performance with LR analysis with the time 
covariate. Left, distribution plot of P values resulting from the AUC test. 
Right, distribution plot of P values resulting from the LR analysis. The 
pie chart shows the number of differentially expressed genes (q < 0.1) for 
both methods and the overlapping number. b, Top, comparison of results 
from paired t-test (two-sided) with DESeq2 method (Wald test) for stage 
pairwise analyses (for example, EE versus personal healthy baseline). 
Seventy-one per cent of transcripts identified by DESeq2 method overlap 
with paired t-test results. Bottom, P value distribution for paired t-test 
(left) and DESeq2 (right). Both methods show a homogenous distribution 
of P values with enrichment for significant ones. Supplementary Table 39 
lists molecules found significant by paired t-test or DESeq2 method.  
c, Illustration of IL10 pathway enriched in response to RVI. Multi-omic 
molecules that changed significantly during the course of RVI by AUC 
test are highlighted in red (upregulated) or green (downregulated). d, An 
example of enriched neuroinflammation signalling showing molecules 
significantly upregulated (red) or downregulated (green) in response to 
RVI. Simplified pathway graph is shown in Fig. 3a (bottom). e, Illustration 
of insulin signalling (left) and cardiac hypertrophy (right) pathways, which 
were enriched in response to RVI. Molecules that changed significantly 
during the course of RVI by AUC test are highlighted in dark pink 
(upregulated) or green (downregulated).
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Extended Data Fig. 5 | Trend analysis of differential changes in 
response to RVI. n = 156 RVI categorized time points and n = 89 healthy 
time points based on AUC test, two-sided. a, Four time-course patterns 
clustered by differential ’omic molecules that changed in response to RVI. 
b, The elbow method showed the optimal number of clusters (K = 4). 
c, Example of co-occurring changes in nasal and stool bacteria during 
upper respiratory rhinovirus infection. In subject ZOZOW1T, a high 
load of human Rhinovirus was found in RVI EE stage, accompanied 
by an increase in Moraxella (80%) in nasal samples. The abundances of 
Rhinovirus and Moraxella in nasal samples decreased in RVI EL and 
continued to decrease during the RE stage. Rhinovirus could not be 
detected at the next healthy time point and Moraxella showed a relatively 
low abundance (5%). Bacteroides, the dominant genus in the stool 
samples, decreased by 40% from EE to EL and returned to the level of the 
previous healthy time point at the RE stage. Rhinovirus was identified 
by nasal transcriptome and quantified by mapping the transcriptome 
reads to the virome references database. Moraxella and Bacteroides in 
nasal and stool samples were identified and quantified by 16S rRNA gene 
sequencing. d, Acute phase response pathway representation upon RVI in 
the insulin-sensitive group (left; Z-score 3.9 at EE stage) and the insulin-
resistant group (right; Z-score 1.2 at EE stage). Upregulated molecules are 
highlighted in red, downregulated ones in green.
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Extended Data Fig. 6 | Trend analysis of differential changes in response 
to RVI and immunization. Data include 117 immunization (VAC) and  
59 healthy categorized time points based on AUC test, two-sided.  
a, Four time-course patterns clustered by differential ’omic molecules that 
changed in response to immunization. b, The elbow method shows the 
optimal number of clusters (K = 4). c, Heatmap of immune molecules 
that changed significantly in response to RVI and immunization. The 
heatmap uses log2(baseline normalized read counts) to measure changes 
in expression in every category (EE, EL, RE) compared to the personal 
baseline (–H and +H). Red, upregulation; blue, downregulation. d, NF-κB 
pathway upregulation after RVI (Z-score = +1.96). e, NF-κB pathway 
downregulation upon immunization (Z-score = –4.9). Red, upregulated; 
green, downregulated.
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Extended Data Fig. 7 | Trend analysis of differential changes in response 
to respiratory viral infections (RVI, n = 156) and immunization  
(VAC, n = 117). a, Heatmap of cytokine expression over the course of  
RVI and VAC. The heatmap uses log2(baseline normalized read counts)  
to measure changes in expression in every category (EE, EL, RE) 
compared to personal baseline (–H and +H). Red, upregulation; blue, 
downregulation. b–d, Heatmaps of nasal KO genes (b), nasal microbial 
taxa (c) and gut microbial taxa (d) over the course of RVI and VAC. The 
heatmaps use the log2(baseline normalized read counts) to measure 
changes in values in every category (EE, EL, RE) compared to the personal 
baseline (–H and +H).
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Extended Data Fig. 8 | Receiver operating characteristic (ROC) curves 
for classifiers designed to separate RVI time points from healthy 
baselines at different discrimination thresholds. a, b, Performance in the 
training (top) and test sets (bottom) for LR (a) and SVM (b) models. Plots 
show the true positive rate (y axis) versus the false positive rate (x axis) for 
each ’ome and all ’omes combined. AUC scores for ROC curves are listed 
on the right for classification accuracy. For binary classification between 
healthy and RVI data, combined multi-omes had the highest prediction 
performance, followed by the metabolome, compared to others in the 
test cohort. c, ROC curves and AUC scores based on all-pairs testing 
using the LR model for classifying RVI events. The plot shows the true 
positive rate (y axis) versus the false positive rate (x axis) for each pairwise 
combination. Bottom right, summary of all pairwise combinations of 
multi-omes and their respective AUC scores in percentages.
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Extended Data Fig. 9 | ROC curves for classifiers designed to separate 
immunization time points from healthy baselines at different 
discrimination thresholds. a, b, Performance in the training (top) and 
test sets (bottom) for LR (a) and SVM (b) models. Plots show the true 
positive rate (y axis) versus the false positive rate (x axis) for each ’ome 
and all ’omes combined. AUC scores of ROC curves are listed on the 
right for classification accuracy. For binary classification between healthy 
and immunization, combined multi-omes had the highest prediction 
performance, followed by metabolomes, compared to others in the test 
cohort. c, ROC curves and AUC scores based on all-pairs testing using the 
LR model for classifying immunization events. The plot shows the true 
positive rate (y axis) versus the false positive rate (x axis) for each pairwise 
combination. Bottom right, summary of all pairwise combinations of 
multi-omes and their respective AUC scores in percentages.
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Extended Data Fig. 10 | See next page for caption.
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Extended Data Fig. 10 | Associations among multi-omic molecules. 
Insulin-resistant n = 215, insulin-sensitive n = 238, all n = 624 including 
baselines from individuals with unknown insulin sensitivity, Rmcorr 
correlation. a, Comparison of associations between A1C and fasting 
glucose level (GLU) for between-individual associations (at the cohort 
level, top) and within-individual associations (at individual level, bottom) 
in insulin-resistant and insulin-sensitive groups. Correlation coefficients 
and adjusted P values (B–H corrected) are shown in each comparison.  
For comparison, data from individuals are coloured differently, with a 
single colour for all time points from the same individual. At the cohort 
level, the median fasting plasma glucose per participant correlated 
positively with the median haemoglobin A1C level for both insulin-
sensitive and insulin-resistant groups. However, at the individual level, 
there was no significant correlation. This is expected, as fasting glucose is 
very variable and can be affected by diet or lifestyle within hours, whereas 
A1C approximates average glucose levels over about 3 months.  
b, Associations with HSCRP are shown either at the cohort level  
(left, between-individual correlation) or at individual level (right, within-
individual correlation) for comparison between insulin-resistant and 
insulin-sensitive individuals. Only significant associations (q < 0.05) in 
insulin-resistant or insulin-sensitive subjects at individual level are used 
as examples. c, Significant (by SparCC) association patterns between gut 
microorganisms at the genus level in insulin-sensitive (left) and insulin-
resistant individuals (right, insulin-sensitive n = 190, insulin-resistant  
n = 184, as not all visits included stool sampling). Red, positive correlation; 
blue, inverse correlation. d, An example of gut microorganisms: genus 
Butyricimonas and its significant associations with host metabolites (by 
CLR+rmcorr) that are specific to insulin-sensitive or insulin-resistant 
groups. Black dots denote the correlation coefficients of the genus related 
to corresponding metabolites on the left, with their 95% confidence 
intervals shown as either green ribbons for insulin-sensitive-specific or red 
ribbons for insulin-resistant-specific associations. The P values of those 
associations are shown on the right.
ArticlereSeArcH
Extended Data Fig. 11 | Personal features reveal molecular markers 
before the onset of diseases. a, Left, scatter plot showing the number of 
outliers among thousands of molecules for each participant; right: the 
percentage of outliers contributed by each ’ome. The top part of the plot 
is also shown in Fig. 6a. b) Z-scores of outlier molecules in participant 
ZJTKAE3. c, Metabolite–cytokine profiles of the cohort. All healthy 
baselines (H1–H8) of participant ZNED4XZ are highlighted in red.  
d, Correlational network among molecules that were highly associated 
with IL1RA and enriched in xenobiotic-induced immune response 
pathways. Metabolites, orange ovals; transcripts, blue rectangles; proteins, 
yellow squares. Positive associations, green lines; negative associations,  
red lines.
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Progenesis QI for metabolomics data, pyProphet for proteomics data
Data analysis Open-sourced and standard packages include: TopHat, HTseq, DESeq2, Uchime, 
Usearch, RDP-classifer, QIIME, TRIC, Perseus.   
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Raw data included in this study are hosted on the NIH Human Microbiome 2 project site (https://portal.hmpdacc.org) with no restrictions for its use. Exome 
sequencing data are also available at dbGaP under Study Accession phs001719.v1.p1.
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Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Sample size for the main HMP project was calculated based on the pilot iPOP study findings of levels of autocorrelation in multiomics data and 
the number of timepoints needed per participant to reconstruct the time series with < 1% uncertainty. Additionally, our observational study is 
different from traditional cross-section study in two aspects: 1) We sample more than one time longitudinally in each of the participants; 2) 
We focus on naturally or spontaneously occurring physiological states. For group-wise comparison, we examined on those had at least 30 
individuals or events per group (IR vs IS, Infection vs healthy, Immunization vs infection etc) and used statistical analyses to take the sample 
size into account. For our analyses focusing on individual characters, we examined on those participants who had at least three independent 
samplings in our study. The sample size is confirmed sufficient by using a stringent significant threshold in downstream statistics.
Data exclusions For microbiome analyses, to capture major changes across the whole cohort, we focused on prevalent taxa and genes out of all mapped ones, 
excluding those that were present in less than half of the cohort.
Replication To control data generation reproducibility, we included multiple aliquots for selected samples anonymously in different batches of all omic 
assays, and make sure replicates were similar to each other than to any other samples.
Randomization Samples were randomly arranged by computing program into various batches of omics assay. 
Blinding Each sample was labeled with a randomized ID whose annotation and clinical status were kept blinded during data collection and analyses.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Human research participants
Policy information about studies involving human research participants
Population characteristics 55 participants in this study were female and 51 male, with ages ranging from 25 to 75 yrs old 
and BMI 25-40 kg/m2. More information were provided in Methods and Supplemental Table 
1.
Recruitment Participants were recruited via placement of advertisements in local newspapers and radio stations seeking “prediabetic 
volunteers” at risk for Type 2 diabetes for longitudinal multi-omic study. Screening in the CTRU entailed history and physical, 
anthropometric measurements, and fasting blood tests for exclusions including presence of anemia defined as hematocrit < 30, 
renal disease defined as creatinine > 1.5, history of any cardiovascular, malignancy, chronic inflammatory, psychiatric disease, 
and history of any bariatric surgery or liposuction. 
Ethics oversight Stanford University Institutional Review Board (IRB 23602)
Note that full information on the approval of the study protocol must also be provided in the manuscript.
